RG
ACHL

Redmile Group’s Achilles Therapeutics ACHL Stock Holding History

Redmile Group’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,608,089
Closed -$1.83M – 64
2024
Q4 		$1.83M Hold
1,608,089
– – 0.13% 56
2024
Q3 		$1.64M Hold
1,608,089
– – 0.1% 59
2024
Q2 		$1.31M Hold
1,608,089
– – 0.08% 59
2024
Q1 		$2.01M Hold
1,608,089
– – 0.07% 72
2023
Q4 		$1.43M Hold
1,608,089
– – 0.05% 62
2023
Q3 		$1.46M Hold
1,608,089
– – 0.07% 61
2023
Q2 		$1.52M Hold
1,608,089
– – 0.06% 67
2023
Q1 		$1.54M Hold
1,608,089
– – 0.07% 69
2022
Q4 		$1.45M Hold
1,608,089
– – 0.06% 62
2022
Q3 		$3.63M Hold
1,608,089
– – 0.14% 61
2022
Q2 		$4.05M Hold
1,608,089
– – 0.15% 60
2022
Q1 		$4.73M Sell
1,608,089
-480,000
-23% -$1.7M 0.15% 62
2021
Q4 		$10.5M Hold
2,088,089
– – 0.24% 59
2021
Q3 		$16.3M Hold
2,088,089
– – 0.28% 59
2021
Q2 		$20.4M Hold
2,088,089
– – 0.3% 64
2021
Q1 		$34.6M Buy
+2,088,089
New +$34.6M 0.49% 55

Other funds holding ACHL

XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Redmile Group's ACHL Position: Q1 2025 in Review

Redmile Group sold out of Achilles Therapeutics (ACHL) in Q1 2025, closing a stake of 1,608,089 shares — an estimated $1.83M sold.

Redmile Group first reported a position in ACHL in Q1 2021 and held it in 16 quarters. The position peaked at $34.6M in Q1 2021. 6 funds tracked by Wall St. Rank hold ACHL as of Q1 2025.

  • Redmile Group reported no remaining Achilles Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Redmile Group sold 1,608,089 Achilles Therapeutics shares in Q1 2025, an estimated $1.83M.
  • Redmile Group first reported a position in Achilles Therapeutics in Q1 2021 and held it in 16 quarters.
  • Redmile Group's Achilles Therapeutics position peaked at $34.6M in Q1 2021.
  • 6 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2025.

Based on Redmile Group's 13F filing for Q1 2025, filed 15 May 2025.